Press Release

Cellectis S.A.'s first combined Annual and Special Shareholders General Meeting, May 30, 2007.

Romainville, France - May the 30^th, 2007 - the first combined Annual and Special General Meeting of the shareholders of Cellectis S.A. (Alternext: FR0010425595; ALCLS) took place today under the chairmanship of Christian Policard and in the presence of the company's Board members and senior management.

All the resolutions submitted to the General Meeting were approved, except for that seeking to delegate the shareholders' power to implement one or more reserved share capital increases for company savings plan members to the Board of Directors. During the Meeting, André Choulika and Marc Le Bozec (Cellectis' CEO and VP Finance, respectively) presented the company's strategy, financial results and key events from 2006 and the first quarter of 2007, together with the corporate outlook.

The shareholders notably approved the following items:
1) as part of the Annual General Meeting:

• the corporate financial statement and the consolidated accounts for the fiscal year ending Dec 31, 2006.
• attribution of the company's trading results for the fiscal year ending Dec 31, 2006.
• nomination of Richard Mulligan PhD as a Board member.

• modification of Article 18 of the company's bylaws so as to ensure its compliance with the French governmental decree No. 2006-1566 dated Dec 11, 2006.
• the authorization given to the Board with respect to the issue of up to 250,000 stock warrants for company founders (giving the right to subscribe to up to 250,000 company shares), with the abolition of preferential share subscription rights for the company's employees and officers.
• the authorization given to the Board with respect to the issue of up to 250,000 stock warrants for up to 250,000 ordinary shares, with abolition of preferential share subscription rights for Board members who at the date of warrant issue are not company employees or officers and for independent members of any ad hoc committees created by the Board.

Practical information:

About Cellectis:

Cellectis SA (www.cellectis.com) is a world-leading company in genome engineering and genome surgery. It focuses on developing new tools for rational reverse genetics and targeted recombination. In particular, Cellectis designs meganucleases (small proteins) that cut DNA at a highly precise, chosen location in a genome and nowhere else. Genomic DNA breaks are repaired naturally by the DNA maintenance system present in all living organisms. Cellectis combines the ability of meganucleases to cut DNA at a single, chosen location with natural DNA repair, in order to offer new-generation products for a wide spectrum of applications:

• Human health: Meganucleases that target a gene responsible for a genetic disease are transferred into human cells, together with a DNA repair matrix which includes the correct sequence for the mutated gene. After the DNA break occurs (which takes just a few minutes), the right sequence is copied into the genome of the patients' cells and the gene is thus repaired. This process - termed "genome surgery" - has a defined time-frame of action with permanent effects. All other transferred material is degraded by natural mechanisms.
  
  
• Agrobiotech: The same process used in human healthcare can be applied to plants, with the objective of replacing one gene by another, modifying the gene or shutting it down. The applications developed using Cellectis' technology are essentially focused on improving agronomic features of crops, producing new generations of biofuels and developing better biofibers.
  
  
• BioProduction: BioProduction is the production of therapeutic proteins and antibodies using bacteria, yeasts or mammalian cells (mouse, hamster and human cells). This multibillion market has an annual growth rate of over 15%. Cellectis has developed meganucleases that cut the DNA of major production cell lines used in BioProduction, thus enabling the end users (contract manufacturing organizations and biopharmaceutical companies) to shorten their cell line engineering processes, stabilize production yields and thus improve the quality and features of the final product.

In the long term, Cellectis intends to become the global leader in genome engineering. To this end, Cellectis is seeking to establish its rational genome engineering approach (based on meganucleases with modified specificity) as an industry standard.

In the short and medium term, Cellectis intends to achieve profitability by commercializing its technology (primarily in the agrobiotech and bioproduction fields) and, in parallel, building its own therapeutic pipeline (thus providing shareholders with medium- and long-term value).